Haemonetics (HAE) Gains from Investment Securities (2009 - 2026)

Haemonetics' Gains from Investment Securities history runs 17 years deep, the most recent figure standing at -$4.2 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 297.16% year-over-year to -$4.2 million; the TTM figure through Mar 2026 stood at $714000.0 (down 95.45% YoY), while the FY2026 annual figure was $714000.0, down 95.45% from the prior year.
• Gains from Investment Securities was -$4.2 million for Q1 2026 at Haemonetics, down from $4.6 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $33.2 million in Q2 2023 to a low of -$17.8 million in Q3 2025.
• Historically, Gains from Investment Securities has averaged $3.8 million across 5 years, with a median of $2.2 million in 2025.
• Biggest YoY gain for Gains from Investment Securities was 636.07% in 2025; the steepest drop was 5793.91% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at -$13.4 million in 2022, then surged by 61.22% to -$5.2 million in 2023, then jumped by 83.35% to -$865000.0 in 2024, then jumped by 636.07% to $4.6 million in 2025, then tumbled by 191.46% to -$4.2 million in 2026.
• The last three Gains from Investment Securities figures came in at -$4.2 million (Q1 2026), $4.6 million (Q4 2025), and -$17.8 million (Q3 2025), per Business Quant data.